Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Cash & Equivalents (2018 - 2025)

Dna X's Cash & Equivalents history spans 8 years, with the latest figure at $1.3 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $1.3 million for Q4 2025, down 75.61% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (down 75.61% YoY), and the annual figure for FY2025 was $1.3 million, down 75.61%.
  • Cash & Equivalents for Q4 2025 was $1.3 million at Dna X, down from $2.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $13.9 million in Q1 2021 to a low of $102000.0 in Q2 2024.
  • The 5-year median for Cash & Equivalents is $2.1 million (2025), against an average of $5.0 million.
  • The sharpest move saw Cash & Equivalents plummeted 98.95% in 2024, then skyrocketed 1974.76% in 2025.
  • Year by year, Cash & Equivalents stood at $11.2 million in 2021, then tumbled by 86.64% to $1.5 million in 2022, then soared by 526.05% to $9.4 million in 2023, then tumbled by 43.14% to $5.3 million in 2024, then tumbled by 75.61% to $1.3 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $1.3 million, $2.1 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.